Compare OOMA & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | STRO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.7M | 332.8M |
| IPO Year | 2015 | 2018 |
| Metric | OOMA | STRO |
|---|---|---|
| Price | $20.80 | $15.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $26.60 | ★ $47.23 |
| AVG Volume (30 Days) | ★ 391.3K | 284.8K |
| Earning Date | 08-26-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $114,490,000.00 | $38,419,000.00 |
| Revenue This Year | $21.68 | N/A |
| Revenue Next Year | $4.82 | N/A |
| P/E Ratio | $106.70 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $0.72 |
| 52 Week High | $26.19 | $43.85 |
| Indicator | OOMA | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 31.62 |
| Support Level | $19.66 | $14.81 |
| Resistance Level | $21.57 | $17.33 |
| Average True Range (ATR) | 0.80 | 0.92 |
| MACD | -0.31 | 0.21 |
| Stochastic Oscillator | 0.65 | 44.34 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.